

05 Sep 2021 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: new US warnings for JAK inhibitors; strong new heart failure results for Jardiance; good head-to-head results for Pfizer in atopic dermatitis; US payers and drug exclusion lists; and a look ahead at key expected hematology launches.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 3 September 2021, including: US warnings for JAK inhibitors; strong new heart failure results for Jardiance; good head-to-head results for [Pfizer Inc.](#) in atopic dermatitis; US payers and drug exclusion lists; and a look ahead at key expected hematology launches.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[FDA Warnings And Restrictions On JAKs Curb Growth Potential Of Big Brands](#)" - Scrip, 1 Sep, 2021.)

(Also see "[BI/Lilly's Jardiance Crowned As Heart Failure Game Changer After EMPEROR-Preserved](#)" - Scrip, 29 Aug, 2021.)

(Also see "[Pfizer's Oral Abroctinib Bests Injectable Dupixent In Atopic Dermatitis Trial](#)" - Scrip, 30

Aug, 2021.)

(Also see "[*The Booming Business Of Drug Exclusions*](#)" - Scrip, 27 Aug, 2021.)

(Also see "[*Five Hematology Drug Launches To Look Out For In 2022*](#)" - Scrip, 30 Aug, 2021.)

[Click here to explore this interactive content online](#) ✨